Cargando…

National medicines policies – a review of the evolution and development processes

OBJECTIVES: Continuous provision of appropriate medicines of assured quality, in adequate quantities, and at reasonable prices is a concern for all national governments. A national medicines policy (NMP) developed in a collaborative fashion identifies strategies needed to meet these objectives and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoebert, Joëlle M, van Dijk, Liset, Mantel-Teeuwisse, Aukje K, Leufkens, Hubert GM, Laing, Richard O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987068/
https://www.ncbi.nlm.nih.gov/pubmed/24764540
http://dx.doi.org/10.1186/2052-3211-6-5
_version_ 1782311826524995584
author Hoebert, Joëlle M
van Dijk, Liset
Mantel-Teeuwisse, Aukje K
Leufkens, Hubert GM
Laing, Richard O
author_facet Hoebert, Joëlle M
van Dijk, Liset
Mantel-Teeuwisse, Aukje K
Leufkens, Hubert GM
Laing, Richard O
author_sort Hoebert, Joëlle M
collection PubMed
description OBJECTIVES: Continuous provision of appropriate medicines of assured quality, in adequate quantities, and at reasonable prices is a concern for all national governments. A national medicines policy (NMP) developed in a collaborative fashion identifies strategies needed to meet these objectives and provides a comprehensive framework to develop all components of a national pharmaceutical sector. To meet the health needs of the population, there is a general need for medicine policies based on universal principles, but nevertheless adapted to the national situation. This review aims to provide a quantitative and qualitative (describing the historical development) study of the development process and evolution of NMPs. METHODS: The number of NMPs and their current status has been obtained from the results of the assessment of WHO Level I indicators. The policy formulation process is examined in more detail with case studies from four countries: Sri Lanka, Australia, former Yugoslav Republic of Macedonia and South Africa. RESULTS: The number of NMPs worldwide has increased in the last 25 years with the highest proportional increase in the last 5–10 years in high-income countries. Higher income countries seem to have more NMP implementation plans available and have updated their NMP more recently. The four case studies show that the development of a NMP is a complex process that is country specific. In addition, it demonstrates that an appropriate political window is needed for the policy to be passed (for South Africa and the FYR Macedonia, a major political event acted as a trigger for initiating the policy development). Policy-making does not stop with the official adoption of a policy but should create mechanisms for implementation and monitoring. The NMPs of the FYR Macedonia and Australia provide indicators for monitoring. CONCLUSIONS: To date, not all countries have a NMP since political pressure by national experts or non-governmental organizations is generally needed to establish a NMP. Case studies in four countries showed that the policy process is just as important as the policy document since the process must create a mechanism by which all stakeholders are brought together and a sense of collective ownership of the final policy may be achieved.
format Online
Article
Text
id pubmed-3987068
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39870682014-04-16 National medicines policies – a review of the evolution and development processes Hoebert, Joëlle M van Dijk, Liset Mantel-Teeuwisse, Aukje K Leufkens, Hubert GM Laing, Richard O J Pharm Policy Pract Review OBJECTIVES: Continuous provision of appropriate medicines of assured quality, in adequate quantities, and at reasonable prices is a concern for all national governments. A national medicines policy (NMP) developed in a collaborative fashion identifies strategies needed to meet these objectives and provides a comprehensive framework to develop all components of a national pharmaceutical sector. To meet the health needs of the population, there is a general need for medicine policies based on universal principles, but nevertheless adapted to the national situation. This review aims to provide a quantitative and qualitative (describing the historical development) study of the development process and evolution of NMPs. METHODS: The number of NMPs and their current status has been obtained from the results of the assessment of WHO Level I indicators. The policy formulation process is examined in more detail with case studies from four countries: Sri Lanka, Australia, former Yugoslav Republic of Macedonia and South Africa. RESULTS: The number of NMPs worldwide has increased in the last 25 years with the highest proportional increase in the last 5–10 years in high-income countries. Higher income countries seem to have more NMP implementation plans available and have updated their NMP more recently. The four case studies show that the development of a NMP is a complex process that is country specific. In addition, it demonstrates that an appropriate political window is needed for the policy to be passed (for South Africa and the FYR Macedonia, a major political event acted as a trigger for initiating the policy development). Policy-making does not stop with the official adoption of a policy but should create mechanisms for implementation and monitoring. The NMPs of the FYR Macedonia and Australia provide indicators for monitoring. CONCLUSIONS: To date, not all countries have a NMP since political pressure by national experts or non-governmental organizations is generally needed to establish a NMP. Case studies in four countries showed that the policy process is just as important as the policy document since the process must create a mechanism by which all stakeholders are brought together and a sense of collective ownership of the final policy may be achieved. BioMed Central 2013-07-10 /pmc/articles/PMC3987068/ /pubmed/24764540 http://dx.doi.org/10.1186/2052-3211-6-5 Text en Copyright © 2013 Hoebert et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Hoebert, Joëlle M
van Dijk, Liset
Mantel-Teeuwisse, Aukje K
Leufkens, Hubert GM
Laing, Richard O
National medicines policies – a review of the evolution and development processes
title National medicines policies – a review of the evolution and development processes
title_full National medicines policies – a review of the evolution and development processes
title_fullStr National medicines policies – a review of the evolution and development processes
title_full_unstemmed National medicines policies – a review of the evolution and development processes
title_short National medicines policies – a review of the evolution and development processes
title_sort national medicines policies – a review of the evolution and development processes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987068/
https://www.ncbi.nlm.nih.gov/pubmed/24764540
http://dx.doi.org/10.1186/2052-3211-6-5
work_keys_str_mv AT hoebertjoellem nationalmedicinespoliciesareviewoftheevolutionanddevelopmentprocesses
AT vandijkliset nationalmedicinespoliciesareviewoftheevolutionanddevelopmentprocesses
AT mantelteeuwisseaukjek nationalmedicinespoliciesareviewoftheevolutionanddevelopmentprocesses
AT leufkenshubertgm nationalmedicinespoliciesareviewoftheevolutionanddevelopmentprocesses
AT laingrichardo nationalmedicinespoliciesareviewoftheevolutionanddevelopmentprocesses